fentanyl pfizer transdermal patch 0075mg h - search results

viatris limited - fentanyl 10.2mg (alkaloid powder) - transdermal patch - 100 mcg/h - active: fentanyl 10.2mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 25 square centimeters polyester release liner (scotchpak 1022) 37.34 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

fentanyl viatris

viatris limited - fentanyl 1.28mg (alkaloid powder) - transdermal patch - 12 mcg/h - active: fentanyl 1.28mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 3.13 square centimeters polyester release liner (scotchpak 1022) 10.16 square centimetres no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

fentanyl viatris

viatris limited - fentanyl 2.55mg (alkaloid powder) - transdermal patch - 25 mcg/h - active: fentanyl 2.55mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 6.25 square centimeters polyester release liner (scotchpak 1022) 13.21 square centimetres no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

fentanyl viatris

viatris limited - fentanyl 5.1mg (alkaloid powder) - transdermal patch - 50 mcg/h - active: fentanyl 5.1mg (alkaloid powder) excipient: dimeticone polyolefin film (mediflex 1000) 12.5 square centimeters polyester release liner (scotchpak 1022) 22.35 square centimeters no-tox white fgn-4194 nt23 silicone adhesive - mylan fentanyl patch is indicated in the management of chronic cancer pain. mylan fentanyl patch is also indicated in the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. it is indicated for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.